Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.95 USD
Change Today +0.01 / 0.08%
Volume 1.7M
NVAX On Other Exchanges
As of 12:03 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - $13.12
52 Week Low
10/2/14 - $3.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, as well as pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, as well as rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

325 Employees
Last Reported Date: 05/7/15
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $487.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $389.8K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $291.7K
Compensation as of Fiscal Year 2014.

novavax inc (NVAX) Key Developments

Novavax, Inc. Announces Positive Top-Line Data from Phase 1 Ebola Vaccine Trial on WHO Teleconference

Novavax, Inc. announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing. The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points including days 28 and 35. The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35. The adjuvanted single dose vaccine regimen induced GMEU between 1,700 and 3,400, representing a 21 to 27-fold rise over baseline at day 35.

Novavax, Inc. Announces Second Amended and Restated Certificate of Incorporation

Novavax, Inc. announced that at its AGM held on June 18, 2015, shareholders approved the company's second amended and restated certificate of incorporation which increases the total number of authorized shares of the company's common stock, $0.01 par value from 300,000,000 shares to 600,000,000 shares.

Novavax, Inc. Appoints Gail K. Boudreaux to its Board of Directors

Novavax, Inc. announced appointment of Gail K. Boudreaux to its Board of Directors. Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $11.96 USD +0.0199

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $26.34 USD +0.01
Dynavax Technologies Corp $29.30 USD -0.35
Inovio Pharmaceuticals Inc $7.20 USD -0.20
Progenics Pharmaceuticals Inc $8.40 USD -0.03
ZIOPHARM Oncology Inc $12.85 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 88.9x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 88.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at